Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2015 - 2026)

Corvus Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 702.2% year-over-year to $40.1 million; the TTM figure through Mar 2026 stood at $40.1 million (up 702.2% YoY), while the FY2025 annual figure was $4.6 million, down 47.64% from the prior year.
• Cash & Equivalents was $40.1 million for Q1 2026 at Corvus Pharmaceuticals, up from $4.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $40.1 million in Q1 2026 to a low of $2.9 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $14.7 million across 5 years, with a median of $12.6 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 79.26% in 2022, then jumped 702.2% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $13.2 million in 2022, then decreased by 4.1% to $12.6 million in 2023, then slumped by 30.74% to $8.7 million in 2024, then sank by 47.64% to $4.6 million in 2025, then soared by 776.35% to $40.1 million in 2026.
• The last three Cash & Equivalents figures came in at $40.1 million (Q1 2026), $4.6 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.